CTLA-4 inhibitors are monoclonal antibodies designed to block the CTLA-4 pathway. By inhibiting CTLA-4, these drugs remove the "brakes" on the immune system, allowing T cells to become more active. This heightened immune activity can help the body recognize and attack cancer cells more effectively. The most well-known CTLA-4 inhibitor is ipilimumab, which was the first checkpoint inhibitor approved for cancer treatment.
